Join Us at the 3rd Edition of the Latin America Healthcare and Life Sciences 360 Conference
We are excited to announce we will be joining the 3rd edition of the Latin America Healthcare and Life Sciences 360 Conference on May 6th in São Paulo. This event, organized by Trench Rossi Watanabe brings together key industry leaders and Baker McKenzie speakers to discuss the latest trends and developments in healthcare and life sciences.
The conference agenda promises a day full of insightful discussions on a variety of critical topics, including market expectations, regulatory changes, market access, data privacy, and ethical AI. Our roster of expert speakers will provide valuable insights and share their extensive knowledge on these subjects.

In addition to the stimulating sessions, attendees will have the opportunity to network with industry experts and peers. Don’t miss out on this chance to gain a deeper understanding of the healthcare and life sciences landscape in Latin America.

For more details and to register for the event, please click here. We look forward to seeing you there!

On 7 August 2023, Decree 405/2023 (“Decree”) was published to regulate Law No. 27,669 that states the regulatory framework for the development of the medicinal cannabis and industrial hemp industry. Further, the Decree: (i) regulates the chain of domestic production and commercialization and/or for export purposes of the cannabis plant, its seeds, and its derivative products for medicinal use, including scientific research and industrial use; and (ii) complements Law No. 27,350, which initially regulated the medical and scientific research of the medicinal use of the cannabis plant and its derivatives.

The Anti-Corruption Office has enabled the registration and use of the Registry of Integrity and Transparency of Companies and Entities (RITE), after announcing its establishment in April 2021. The purpose of the RITE is to contribute to the development, improvement and maturity of the integrity programs as provided for in Law 27,401; the exchange of good practices; and promote transparent business and market environments.

Explore Data PULSE, a platform which helps you to navigate the complex landscape of data, regulatory and IP protection concerns at each stage of the medical product life cycle. As you navigate through each key issue, Data PULSE will help you to identify and mitigate risks across multiple jurisdictions and optimize your strategy through research, market authorization and post-market study phases.

The guide provides the latest developments and updates to in-house counsel and business executives on: regulations and compliance; clinical trials; marketing, manufacturing and distribution of pharmaceuticals and medical devices; pricing; digital health; patents; and COVID-19.

In this edition of the anti-bribery and anti-corruption review, you will find an incisive overview of the legal and regulatory frameworks established to combat white-collar crime in major jurisdictions. With a focus on the practical implications of recent enforcement trends and policies, our lawyers examine key issues such as domestic and foreign bribery, associated offenses including money laundering, and best practices for internal compliance programs.

Mainly during the pandemic, the use of technological resources for performing a job has significantly grown. As a result, the access to such resources in the context of internal investigations has become almost a must. This triggers relevant concerns from a data privacy and a labor perspective.

With the annual J.P. Morgan Healthcare Conference pivoting to a virtual format again in 2022, we will be hosting a lineup of virtual events and reports aligned with the industry’s biggest conference.

How do life sciences companies intend to leverage new and existing sources of growth? Explore the trajectory of life sciences transactions in our latest report.

As digital transformation reshapes business models with different emphases across regions, digitally enabled strategies are helping companies transition from product-only offerings to product-service hybrids, orient to patient mapping, pre-diagnostics solutions and enhancing treatment administration.